Best for Immune Support

Thymosin alpha-1 demonstrates strong evidence for immune enhancement in humans across multiple clinical conditions, with consistent improvements in T-cell markers (CD4+, CD4+/CD8+ ratio) and reduced infection/mortality rates in controlled trials. Multiple meta-analyses and RCTs show clinically meaningful efficacy, though most studies come from China and independent replication outside this region remains limited.

Vitamin D3 supplementation demonstrates strong evidence for immune function enhancement in humans, with multiple RCTs showing reduced infection rates, improved immune cell balance, and modulation of inflammatory markers. Clinical efficacy is proven for specific outcomes like COVID-19 severity and respiratory infections, though optimal dosing strategies remain under investigation.

Probiotics demonstrate proven efficacy for immune function in humans through multiple RCTs and meta-analyses, with consistent improvements in inflammatory markers, respiratory infection symptoms, and immune-related outcomes. Evidence is robust but primarily from moderate-sized studies; larger replicated trials would elevate to Tier 5.

Tesamorelin reduces circulating immune activation markers and modulates hepatic immune pathways in HIV-infected individuals with fatty liver disease, but evidence is limited to 6 human RCTs with moderate sample sizes and lacks broad immune outcome assessment beyond specific protein panels.

Thymalin demonstrates probable efficacy for immune support in humans based on multiple observational studies showing improvements in T-lymphocyte counts, immune markers, and clinical outcomes. However, evidence is limited by very few RCTs, small sample sizes, and lack of independent replication by non-Russian research groups.

Prostatilen shows probable efficacy for immune support based on 4 human observational studies demonstrating improvements in immunological markers (T-lymphocyte counts, phagocyte activity) and immune-related clinical outcomes in urogenital inflammation. However, evidence is limited to observational designs without placebo controls or RCTs, and all studies originate from the same research group.

Zinc supplementation shows probable but not conclusive benefit for immune function and certain respiratory infections, with strongest evidence for reducing symptom duration in respiratory tract infections and improving inflammatory markers in HIV patients. However, efficacy for preventing respiratory infections in healthy populations is limited, and results are inconsistent across populations and study designs.

Curcumin shows probable efficacy for immune support in humans, particularly for reducing inflammatory markers and improving outcomes in respiratory infections and COVID-19, though evidence remains limited by small sample sizes and inconsistent study designs.

Quercetin shows probable but inconsistent benefits for immune function in humans, with the strongest evidence for reducing upper respiratory tract infections after intensive exercise. However, multiple human RCTs found no effect on core immune measures like natural killer cell activity, and clinical efficacy remains unproven for most immune outcomes.

Melatonin demonstrates probable immune-modulatory effects in humans based on several small RCTs and observational studies, with consistent improvements in oxidative stress markers and some inflammatory parameters in autoimmune conditions. However, evidence remains limited by small sample sizes, short treatment durations, and inconsistent clinical outcomes across different immune disorders.

Tongkat Ali shows probable efficacy for immune support in humans based on 2 RCTs demonstrating improved immune markers and immunological vigor, but evidence is limited by small sample sizes, short intervention periods, and lack of independent replication.

Black seed oil shows probable immunomodulatory benefits in humans, with evidence from 2 RCTs demonstrating reduced allergy symptoms and disease activity in autoimmune disease, but efficacy remains incompletely proven due to small sample sizes, limited replication, and mixed results in some outcomes.

Elderberry shows probable efficacy for reducing upper respiratory symptoms and modulating immune markers in humans, supported by a meta-analysis and several RCTs, but evidence is limited by small sample sizes, short treatment durations, and lack of independent replication across diverse populations.

Aged garlic extract shows probable efficacy for immune function in humans, with multiple RCTs demonstrating improvements in NK cell activity, inflammatory markers, and cold/flu severity. However, evidence is limited by small sample sizes, short intervention periods, and insufficient independent replication.

Spirulina demonstrates probable immune-enhancing effects in humans and animals, with consistent improvements in immune markers across multiple studies. However, evidence quality is limited by small human sample sizes, lack of independent replication, and reliance on surrogate immune markers rather than clinical disease outcomes.

Vitamin B12 supplementation shows probable immune-enhancing effects in specific populations (pernicious anemia, pregnancy/lactation, viral infections), with measurable improvements in immune markers and vaccine responses. However, evidence remains inconsistent across healthy populations and general immune outcomes.

Vitamin E supplementation shows probable immune benefits in humans, particularly for cell-mediated immunity and antibody responses in older adults, but efficacy is not conclusively proven across all populations or immune measures. Evidence is limited to small human RCTs (n=32) and numerous mechanistic/animal studies.

Iron supplementation shows probable benefit for immune function, particularly for preventing infections and enhancing vaccine responses in iron-deficient individuals. However, evidence is mixed: iron deficiency clearly impairs immunity, but supplementation efficacy in already-adequate populations is unproven, and iron overload may paradoxically worsen some immune conditions.

Selenium supplementation shows probable benefits for immune function and autoimmune conditions in humans, but efficacy is not conclusively proven. Evidence is mixed: while mechanistic studies and some observational data support immune benefits, meta-analyses of supplementation trials show limited effects on standard immune markers in healthy people.

Urolithin A demonstrates probable efficacy for enhancing immune function in humans, supported by one rigorous RCT showing expansion of naive CD8+ T cells and improved NK cell activity, plus consistent mechanistic findings across animal and in-vitro studies. However, the human evidence base remains limited to a single moderate-sized trial, preventing a higher tier classification.

Glutathione supplementation, particularly in liposomal form, shows probable efficacy for immune support in humans with specific immune deficiencies (HIV, tuberculosis, diabetes), with consistent improvements in cytokine balance and antioxidant status across multiple human studies. However, evidence remains limited by small sample sizes, short durations, and lack of independent replication in healthy populations.

Boswellia serrata demonstrates probable immunomodulatory and anti-inflammatory effects in humans based on 2 small RCTs and multiple mechanistic studies, but evidence remains limited by small sample sizes and lack of independent replication in large-scale trials.

Cordyceps shows probable efficacy for enhancing immune function in humans based on one moderate-quality RCT demonstrating improved NK cell activity and Th1 cytokine production. However, evidence remains limited to a single small human trial; broader replication is needed to confirm clinical significance.

Reishi demonstrates immunomodulatory effects in human and animal studies, with one small RCT showing T-lymphocyte regulation in older women. However, efficacy for broad immune support remains plausible but not conclusively proven—most evidence is mechanistic or from animal models.

Pomegranate extract demonstrates immunomodulatory and anti-inflammatory effects supported by multiple human studies and consistent animal data, but evidence remains limited to small human trials and short interventions. Efficacy for immune function is probable but not yet conclusively proven.

Olive leaf extract shows probable efficacy for immune support, with human evidence of reduced upper respiratory illness duration and antiviral activity against HSV-1, but efficacy remains unproven for most immune outcomes due to limited RCT data and inconsistent results.

MSM demonstrates probable immune-supportive effects in humans, particularly in modulating post-exercise inflammatory response and allergic symptoms, but evidence remains limited by small sample sizes and inconsistent methodology. Efficacy is suggested but not conclusively proven across diverse immune outcomes.

Bromelain shows probable immunomodulatory and anti-inflammatory effects in humans based on multiple small RCTs and observational studies, but efficacy remains incompletely proven due to small sample sizes, inconsistent effect measurements, and limited independent replication of clinical outcomes.

Lactoferrin shows probable efficacy for immune support in humans, with consistent evidence from multiple RCTs demonstrating reduced respiratory tract infections in infants/children and improvements in inflammatory markers in adults. However, effect sizes are modest, most human studies are small (n<100), and results for some immune parameters (NK cell activity, CRP) remain inconclusive.

Echinacea shows probable efficacy for supporting immune function and reducing upper respiratory tract infection duration in humans, supported by multiple small RCTs and mechanistic studies. However, evidence quality is limited by small sample sizes, inconsistent study designs, and mixed results on cold prevention.

Rapamycin demonstrates probable efficacy for modulating immune function in humans, with evidence from multiple RCTs showing improved vaccine responses and reduced respiratory infections in older adults. However, efficacy is context-dependent (immunosuppressive in transplant settings, immunostimulatory at lower doses) and long-term clinical outcomes remain incompletely characterized.

Whey protein shows probable benefits for immune function in humans, with several RCTs demonstrating improvements in specific immune markers (antibody response, glutathione levels, anti-inflammatory cytokines). However, evidence remains inconsistent and limited by small sample sizes, short intervention periods, and mixed results across studies.

Astragalus polysaccharides and related compounds show immunomodulatory effects in multiple human clinical trials and meta-analyses, with demonstrated improvements in T-cell counts and immune markers in cancer and autoimmune disease contexts. However, most human evidence comes from small, non-blinded trials conducted in China; rigorous large-scale RCTs with Western populations are absent.

Butyrate shows probable efficacy for immune modulation across multiple human and animal studies, with consistent evidence for anti-inflammatory effects and immune regulation. However, only one human RCT exists; most human evidence is observational, limiting definitive proof of clinical efficacy.

Peppermint oil shows probable benefit for immune-related gastrointestinal dysfunction, particularly in IBS symptom relief through anti-inflammatory mechanisms. However, evidence is limited to 2 human RCTs and mechanistic studies; large-scale independent replication is lacking.

Ginkgo biloba extract shows probable immunomodulatory effects in humans, particularly in restoring T-cell balance and reducing inflammatory markers in specific disease populations. However, evidence is limited to small observational studies and mechanistic animal research; no large-scale human RCTs specifically designed for immune endpoints exist.

L-theanine demonstrates probable efficacy for supporting immune function in humans, with multiple RCTs showing benefits for cold prevention, natural killer cell activity, and immune response to vaccination. However, evidence is limited by small sample sizes and inconsistent findings across different immune parameters.

HMB demonstrates probable efficacy for supporting immune function, particularly in attenuating inflammatory cytokine responses to intense exercise and enhancing specific immune markers in humans. However, evidence is limited to small-to-moderate RCTs and lacks large-scale replication, preventing a higher confidence rating.

BCAAs demonstrate probable efficacy for immune support in humans, particularly during intense exercise and in disease states, with multiple RCTs showing improvements in immune markers and infection reduction. However, evidence is limited by small sample sizes, heterogeneous study populations, and inconsistent effect measures across trials.

L-arginine supplementation shows probable benefits for immune function in humans based on limited clinical evidence, with a meta-analysis demonstrating improved CD4+ T-cell proliferation and reduced infectious complications. However, evidence remains modest due to small human sample sizes, lack of rigorous RCTs, and inconsistent findings across different patient populations.

Larazotide acetate shows probable efficacy for immune-related aspects of celiac disease by restoring intestinal barrier function, with positive results in 3 human RCTs and emerging evidence in MIS-C. However, evidence is limited by small sample sizes, inconsistent dose responses, and lack of independent replication across diverse populations.

Thymopentin shows probable efficacy for immune support in humans, with multiple RCTs and observational studies demonstrating improvements in T-cell counts, immune markers, and infection rates. However, evidence is limited by small sample sizes, short follow-up periods, and heterogeneous patient populations.

Vitamin B3 (nicotinamide) shows emerging evidence for immune support, primarily through NAD+ metabolism and regulatory T cell enhancement in specific conditions like immune thrombocytopenia and HIV, but human efficacy data remain limited to small studies and one specialized population.

Vitamin B6 shows probable efficacy for immune function in humans, demonstrated by multiple small studies showing improvements in lymphocyte responses and immune markers. However, evidence is limited by small sample sizes, short durations, and lack of replication in large, well-controlled trials.

Lutein shows probable immune benefits in humans based on 4 RCTs demonstrating reduced complement system activation and improved immune markers, but effects are modest, study samples are small (n=70-72), and most evidence focuses on complement inhibition rather than direct immune enhancement.

Vitamin A supplementation has demonstrated efficacy in reducing morbidity and mortality from measles and shows immunomodulatory effects in multiple human studies, but evidence for general immune enhancement is inconsistent and sometimes contradictory, with mixed results in vaccination responses and atopic outcomes.

Black pepper (piperine) shows modest immune benefits in humans when combined with curcumin, primarily reducing inflammatory markers in COVID-19 patients and reducing allergic response (IgE) in women with menstrual disorders. However, evidence is limited to small RCTs with mixed results, and most studies test the combination rather than piperine alone.

Moringa shows promising immune-boosting effects in human HIV patients and multiple animal models, with consistent improvements in immune markers and antioxidant status. However, evidence is limited to 2 small human RCTs and predominantly animal studies; larger, independently replicated human trials are needed to confirm clinical significance.

Creatine monohydrate has theoretical immunological relevance based on mechanistic studies and expert review, but direct evidence of immune efficacy in humans is lacking. Animal and in-vitro studies suggest creatine may enhance T cell antitumor immunity and reduce inflammatory markers, but no human RCTs have demonstrated clinically meaningful immune benefits.

Ashwagandha demonstrates immunomodulatory properties in preclinical studies and is classified as an immunostimulatory herb with robust evidence across multiple study types. However, only one human RCT (currently ongoing for long COVID) has been identified, making proven efficacy in humans for immune function unclear.

TB-500 shows immunomodulatory properties in animal models and cell cultures, but human evidence for direct immune benefits is limited to observational studies and disease-specific applications.

Selank shows immunomodulatory effects and gene expression changes in animal studies and one observational human study, but efficacy for immune function is not proven in humans. Clinical relevance remains unclear due to lack of rigorous human trials designed specifically for immune outcomes.

Epithalon shows consistent immunomodulatory effects in animal studies, particularly in restoring thymus function and enhancing T-cell and B-cell differentiation during aging. However, no human clinical trials exist, limiting evidence to animal models and mechanistic studies.

DSIP shows immunomodulatory potential in animal models, but human evidence for immune benefit is absent. The single human study (lung transplant) measured gene expression changes without clinical immune outcomes, making efficacy unproven in humans.

KPV demonstrates consistent anti-inflammatory effects in animal models of colitis and immune dysfunction, with a clear mechanistic basis involving NF-κB inhibition and PepT1-mediated cellular uptake. However, no human RCTs exist; evidence for immune benefits in humans remains unproven.

MOTS-c shows consistent immunomodulatory effects in animal models and limited human observational data, but efficacy for immune health has not been proven in human RCTs. Evidence suggests potential via AMPK activation and anti-inflammatory mechanisms, but clinical translation remains unestablished.

SS-31 shows consistent mechanistic benefits for immune-related outcomes in animal and in-vitro models, primarily through mitochondrial protection and reduction of inflammatory markers. However, no human RCTs or robust human clinical trials directly assessing immune function have been conducted; all human data are observational or incidental findings in disease-specific studies.

Sermorelin (GHRH analog) shows plausible immunomodulatory effects in one human RCT and multiple animal models, but efficacy for immune function in humans remains unproven. Evidence is limited to a single small human trial and mechanistic studies in animal/cell systems.

LL-37 demonstrates broad antimicrobial and immunomodulatory properties in mechanistic and animal studies, but human efficacy for immune support remains unproven. The single human observational study examined gene modulation in a nutraceutical formula without isolating LL-37's independent effect.

Kisspeptin shows plausible immune-modulatory effects in animal models and limited human observational studies, but lacks rigorous human RCT evidence demonstrating efficacy for immune health. Available data suggests kisspeptin may influence T cell dysfunction and autoimmune responses, but clinical significance remains unproven.

GHRP-2 shows anti-inflammatory effects in one animal arthritis model, reducing IL-6 and arthritis symptoms, but no human trials exist for immune function. Efficacy is plausible but unproven in humans.

GHRP-6 shows immunomodulatory effects in animal models and fish studies, enhancing antimicrobial peptide transcription, antibody responses, and anti-inflammatory signaling. However, no human efficacy trials exist — evidence is limited to one human sleep study (which found no immune effect) and predominantly animal/aquaculture research.

Hexarelin shows anti-inflammatory and immunomodulatory potential in animal models of acute lung injury, but evidence is limited to a single animal study with no human trials demonstrating efficacy for immune support.

Melanotan II shows potential immunomodulatory effects in animal models, particularly through mast cell activation and melanocortin receptor signaling, but no human clinical trials for immune function have been conducted. All efficacy evidence is derived from rodent studies.

Gonadorelin (GnRH agonists) modulates immune function in humans and animals, with evidence of increased natural killer cell activity and altered immune cell populations, but efficacy for improving immune outcomes is not clinically proven. Studies are mechanistic rather than demonstrating clinical immune benefit.

Humanin shows plausible anti-inflammatory and immune-modulatory effects primarily in animal models and mechanistic studies, with limited human evidence. One human RCT demonstrated increased humanin levels with combined exercise and astaxanthin in type 2 diabetes, but direct efficacy for immune outcomes in humans remains unproven.

GDF-11 shows emerging immunomodulatory potential in animal and in-vitro studies, but no human RCT evidence exists demonstrating efficacy for immune health. Current evidence is mechanistic and preliminary.

VIP shows immunomodulatory potential in multiple mechanistic pathways and animal models, but no human randomized controlled trials exist demonstrating efficacy. Evidence is based entirely on reviews of animal studies, in-vitro work, and mechanistic analyses—efficacy in humans remains unproven.

Pinealon shows plausible immune-relevant effects in cell culture and one small human study, but efficacy for immune function is not proven in humans. Evidence is limited to mechanistic studies and adaptation markers rather than direct immune outcomes.

Cortagen shows mixed results in animal studies for immune function, with some evidence of modulating macrophage activity but no demonstrated efficacy in human trials. Efficacy remains plausible but unproven.

Vilon shows consistent immunomodulatory effects in animal models and one small human RCT, with evidence suggesting T-cell activation and immune normalization. However, efficacy in humans remains unproven due to the single, small RCT with no independent replication.

Bronchogen shows consistent anti-inflammatory and epithelial regenerative effects in rodent COPD models, but no human studies exist. Efficacy in humans remains unproven.

5-Amino-1MQ shows plausible immune-related efficacy as an NNMT inhibitor in enhancing anti-PD-L1 immunotherapy response in bladder cancer, but evidence is limited to one human observational study with mechanistic support from animal models. Efficacy in humans is not yet proven.

ARA-290 shows consistent immunomodulatory and anti-inflammatory effects across multiple animal models and one small human trial, with plausible mechanisms via the innate repair receptor. However, efficacy in humans remains largely unproven, supported by only a single RCT (n=unclear) in a specific condition (sarcoidosis-associated neuropathy).

Cerebrolysin shows immunomodulatory effects in multiple studies, primarily reducing pro-inflammatory markers and normalizing immune parameters. However, evidence is limited to 1 small human RCT and 5 observational studies; efficacy for immune function as a primary health goal remains plausible but unproven in humans.

MGF shows mechanistic promise for immune modulation based on animal studies and in vitro research, but there is no proven efficacy in humans for immune health. Only one human RCT exists, which did not directly measure immune outcomes as a primary endpoint.

GLP-1 agonists show emerging immunomodulatory effects in preclinical and early clinical studies, with evidence of reduced inflammatory markers and altered immune cell polarization. However, efficacy in humans for immune-related conditions remains largely unproven, with most human data limited to small case series or observational studies without robust control groups.

Retinalamin has been studied in a small human observational trial showing improvements in visual outcomes for retinal abiotrophy, but efficacy for immune function is not directly demonstrated or discussed in available abstracts. Evidence is emerging but not conclusive, and no connection to immune health is established.

Cortexin shows immunomodulatory effects in animal and in-vitro studies, and appears to have some clinical benefits in neurological conditions, but direct evidence for immune-specific efficacy in humans is limited to small observational studies and mechanistic observations.

Omega-3 fatty acids have plausible immunomodulatory mechanisms supported by mechanistic reviews and animal evidence, but human clinical efficacy for immune function remains unproven. Multiple meta-analyses of human trials show null or inconsistent results for clinically meaningful immune outcomes.

Magnesium supplementation modulates immune function in specific contexts (particularly in magnesium-deficient populations), but human efficacy is not conclusively proven for general immune support. Evidence is mixed: some RCTs show immune cell function changes, while others show null results or fail to translate mechanistic effects into clinical benefit.

NAC shows plausible immune-modulating mechanisms in animal and in-vitro studies, with limited human evidence. Most human data comes from observational studies or small trials focused on specific infections (H. pylori, catheter biofilms) rather than general immune function.

Berberine shows plausible immune-modulating effects through multiple mechanistic pathways (AMPK, NLRP3, NF-κB) demonstrated primarily in animal models and in-vitro studies, but human evidence for direct immune benefit remains extremely limited with only 1 human RCT and 3 observational studies identified across 50 total articles.

Resveratrol shows plausible immune-modulating effects in animal models and limited human data, but efficacy in humans remains unproven. Most evidence comes from poultry and rodent studies; only 2 human RCTs exist, one in chickens (not humans) and one small pilot study (n=5) in autism spectrum disorder.

NMN shows plausible immunological mechanisms in animal and observational human studies, but has NOT demonstrated proven clinical efficacy for immune function in rigorous human trials. The single human RCT (COVID-19, n=42) found NMN safely raised NAD+ levels but did NOT improve immune markers, inflammation, or disease severity.

CoQ10 shows plausible immunomodulatory effects through antioxidant and anti-inflammatory mechanisms in several human studies, but evidence of clinically proven immune benefit remains limited. Current data suggests potential rather than established efficacy.

Alpha-lipoic acid shows plausible immune benefits in animal models and a single small human RCT, with consistent effects on antioxidant markers and immune cell function. However, efficacy in humans remains unproven due to limited human evidence (only 1 RCT, n=33).

Collagen peptides show plausible immune-modulatory mechanisms in animal and mechanistic studies, but human efficacy for immune function remains unproven. Most evidence is indirect—demonstrating effects on skin, thymic cells, or immune biomarkers rather than clinical immune outcomes.

Vitamin K2 shows plausible immune-modulating effects in preliminary human and in-vitro studies, but efficacy for immune health is not yet proven. Evidence is limited to one small human RCT focused on glycemic control (not primary immune outcomes), observational studies showing associations with disease markers, and in-vitro data demonstrating inflammatory cytokine suppression.

Boron shows consistent immune-enhancing effects in animal studies, particularly at moderate doses (10-80 mg/L), with evidence of increased immunoglobulin production, T-cell proliferation, and cytokine expression. However, only one human RCT exists (cardiac outcomes, not immune-specific), leaving efficacy in humans unproven.

Milk thistle shows immunomodulatory effects in animal studies and limited human data, with evidence suggesting it can modulate cytokine production and enhance certain immune markers. However, efficacy in humans for immune function remains largely unproven due to very few rigorous human trials.

Rhodiola rosea demonstrates immunomodulatory and immune-enhancing properties in animal and in-vitro studies, with theoretical mechanisms supported by reviews, but no human RCT evidence of efficacy for immune function exists in this dataset.

Maca root shows promising immunomodulatory effects in animal models and in-vitro studies, with one small human RCT demonstrating increased interferon-γ secretion after exercise. However, efficacy in humans remains largely unproven, and the evidence base consists predominantly of mechanistic studies in cell cultures and animal models rather than definitive clinical trials.

Green tea extract (EGCG) demonstrates immunomodulatory mechanisms in multiple animal and in-vitro studies, but lacks human RCT evidence for immune function. Current evidence is preliminary to emerging, based primarily on mechanistic studies and animal models.

Psyllium husk shows immunomodulatory potential through multiple proposed mechanisms in animal and in-vitro studies, but lacks human RCT evidence demonstrating direct immune enhancement. One observational human study exists, but it focused on gastrointestinal and sleep outcomes rather than immune markers.

Saw palmetto shows modest in vitro and animal evidence for immune modulation, but human clinical trials demonstrate minimal to no effect on immune function. Evidence is emerging but not proven efficacious in humans for immune support.

Fenugreek shows immunomodulatory properties in animal and in-vitro studies, with one human RCT finding no significant immune effects. Evidence is primarily preclinical; human efficacy for immune function is not yet proven.

Glucosamine + Chondroitin has been studied primarily for joint/osteoarthritis outcomes rather than immune function. The limited evidence specifically addressing immune markers shows modest anti-inflammatory effects in humans, but there is no direct demonstration of clinically meaningful immune enhancement.

Vitamin C shows mechanistic promise for immune function through multiple pathways (antioxidant, cofactor for immune enzymes, support for immune cell differentiation), but human clinical efficacy evidence remains limited and inconsistent. Most evidence is mechanistic or from animal models; the single human RCT found no effect.

B vitamin complex shows plausible immune support mechanisms in observational studies and mechanistic reviews, but lacks robust human RCT evidence demonstrating clinical efficacy for immune function. Most findings are associational rather than causal.

Iodine supplementation has not been proven to enhance immune function in humans. Evidence focuses primarily on thyroid autoimmunity, where iodine shows a paradoxical relationship: both deficiency and excess can trigger or exacerbate autoimmune thyroid disease, but no direct immune-boosting efficacy has been demonstrated.

Copper supplementation shows consistent positive effects on immune markers in animal studies and limited human data, but human efficacy remains unproven. Evidence is primarily from animal models and in-vitro work with few rigorous human RCTs.

Chromium supplementation shows consistent effects on immune markers in animal studies (broilers, dairy cows, goats) with improved antibody responses and reduced inflammatory markers, but human evidence is sparse, limited to small pilot studies, and mostly focused on metabolic rather than immune outcomes.

Biotin supplementation shows immunomodulatory effects in human immune cells and is essential for treating biotinidase deficiency, but no rigorous human trials demonstrate efficacy for general immune enhancement. Evidence is primarily mechanistic and observational rather than proof of functional immune benefit.

Fisetin shows consistent anti-inflammatory and immunomodulatory effects in animal models and cell culture, with emerging evidence from early-stage human trials suggesting potential benefits for sepsis and immune-related conditions. However, no completed human RCTs demonstrate proven efficacy for immune function, and clinical translation remains limited.

Spermidine shows consistent mechanistic promise for immune function across animal and human observational studies, with effects on T-cell metabolism, autophagy, and antimicrobial responses. However, no human RCTs establish clinical efficacy, and evidence is primarily mechanistic rather than demonstrating proven therapeutic benefit.

Sulforaphane demonstrates immune-modulating properties primarily through Nrf2 pathway activation in laboratory and animal studies, but human efficacy for immune function remains largely unproven. Available human data is limited to mechanistic observations and small studies without clear demonstration of clinically meaningful immune benefits.

Astaxanthin shows consistent immune-enhancing effects in animal models and aquaculture species, with preliminary evidence from a small human RCT. However, robust human clinical trials demonstrating clinically meaningful immune benefits are lacking.

DIM shows consistent immune-enhancing effects in animal models, particularly increased interferon-gamma production, but no human clinical trials exist to prove efficacy in humans. One mechanistic concern was identified: DIM may inhibit telomerase in normal immune cells at certain doses, potentially limiting long-term safety for chronic supplementation.

Pycnogenol has been studied extensively for immune-related conditions (inflammation, vasculitis, infection), but the evidence remains primarily observational and mechanistic rather than conclusively proving efficacy. No high-quality RCTs specifically testing immune function endpoints exist in the provided abstracts.

TUDCA shows plausible immunomodulatory effects primarily through endoplasmic reticulum stress reduction and inflammasome regulation in animal and cell culture studies, but human evidence for direct immune enhancement is limited to observational studies without robust RCT confirmation.

Shilajit demonstrates immunomodulatory properties in animal and in-vitro studies, with one human RCT showing it as part of a multi-component supplement during exercise intervention. However, efficacy for immune function specifically has not been proven in rigorous human trials.

Colostrum is extensively studied for passive immune transfer in neonatal animals, with strong evidence that maternal antibodies in colostrum protect offspring from infectious disease. However, human efficacy data is minimal—only mechanistic reviews exist, with no robust human RCTs demonstrating clinical immune benefits in humans.

β-Glucans show consistent immunomodulatory effects in animal and mechanistic studies, particularly through trained immunity induction, but human evidence is limited to 1 RCT (vaccine adjuvant) and 3 observational studies. Efficacy in humans for general immune support is plausible but not yet proven.

Turkey Tail mushroom (Trametes versicolor) shows consistent immune-activating effects in animal and in-vitro studies through well-characterized mechanisms involving TLR2 and other immune receptors. However, no human clinical trials are present in this literature set, making efficacy in humans unproven despite mechanistic plausibility.

Chaga mushroom shows plausible immune-enhancing potential based on consistent animal studies and in-vitro data, but human efficacy remains largely unproven. Only one small human observational study exists, which is insufficient to demonstrate real clinical benefit.

Epicatechin shows immunomodulatory potential through multiple mechanistic pathways in cell and animal models, but human efficacy for immune health remains unproven. Only 1 human RCT exists, focused on cardiac ischemia rather than immune outcomes.

Pterostilbene shows consistent immune-modulating effects in animal models and in-vitro studies, with emerging evidence from a single human trial, but clinical efficacy in humans remains unproven. Most evidence comes from rodent and cell-based research rather than rigorous human trials.

Grape seed extract shows consistent immunomodulatory and anti-inflammatory effects across numerous animal studies and a limited number of human observational studies, but lacks rigorous human RCTs needed to prove efficacy for immune support in humans.

Stinging nettle demonstrates immunomodulatory activity in animal and in-vitro studies, with mechanisms involving flavonoid compounds and antimicrobial properties. However, meaningful human evidence of immune efficacy is largely absent—only 2 human RCTs exist, both in animal species (broiler chickens), not humans.

Mucuna pruriens shows immunomodulatory potential in animal models and fish studies, with some mechanistic evidence in rodent macrophages, but human efficacy for immune function remains unproven. The only human RCTs focused on Parkinson's motor symptoms rather than immune outcomes.

Ecdysterone shows emerging immune-modulating properties in animal models and insects, with one human RCT demonstrating 100% parasitic clearance against Giardia lamblia. However, evidence is predominantly from insect and crustacean studies; human efficacy for immune health remains largely unproven.

Turkesterone shows plausible immunomodulatory effects in animal models, but no human clinical trials exist to prove efficacy for immune function. Evidence is limited to one rat study and a C. elegans review.

Cistanche shows immunomodulatory potential primarily through in-vitro and animal studies demonstrating effects on macrophage activation, cytokine production, and inflammatory pathways. However, only 1 small human RCT exists, and human efficacy for immune health remains unproven.

Tribulus terrestris shows no proven efficacy for immune function in humans. While in vitro and animal studies suggest potential immunomodulatory mechanisms, the only rigorous human RCT found no significant improvements in immune markers despite increased testosterone precursors.

Kava-derived compounds, particularly kavain, show TNF-alpha suppression in cell-based assays and protected mice from lethal lipopolysaccharide challenge in a single animal study. However, no human clinical trials have been conducted to establish efficacy for immune support in people.

Lemon balm demonstrates antimicrobial and anti-inflammatory properties in laboratory and animal studies, with limited human evidence. Two small human RCTs suggest benefits for psoriasis and herpes labialis, but efficacy for immune function specifically is not directly proven in humans.

Schisandra chinensis shows plausible immune-supporting effects in animal models and one small human RCT, with consistent mechanistic findings across studies, but human efficacy remains largely unproven due to very limited RCT data and lack of independent replication.

CLA demonstrates immunomodulatory properties in animal models and mechanistic studies, with evidence suggesting effects on T cell proliferation, macrophage polarization, and inflammatory cytokine production. However, human clinical evidence for immune benefits is extremely limited—only 1 human RCT exists, showing reduced pro-inflammatory cytokine release in stroke patients but no clear functional immune improvement.

Methylene blue shows plausible immunomodulatory and antimicrobial effects primarily in animal models and in-vitro studies, but human evidence for immune function is limited to two small RCTs in septic shock contexts with mixed results. Efficacy for general immune support remains unproven in humans.

Pregnenolone shows anti-inflammatory and immunomodulatory properties in mechanistic studies and animal models, but human efficacy for immune health remains unproven. Evidence is limited to observational hormone measurements and in-vitro/animal research with no randomized controlled trials demonstrating clinical immune benefit.

SAMe shows plausible immune-modulating effects in preliminary human studies and mechanistic research, but efficacy for immune function is not proven. Evidence is limited to one small human RCT in hepatitis C and multiple mechanistic/observational studies lacking direct immune outcome measures.

Forskolin shows plausible immune-modulating effects primarily through in vitro studies demonstrating reduced inflammatory cytokine production and enhanced barrier function genes in animal models, but lacks rigorous human clinical trials demonstrating proven efficacy for immune health.

Betaine HCl shows plausible immune-supporting effects in animal models and a limited number of human studies, with evidence of reduced pro-inflammatory cytokines and improved immune markers. However, the human evidence base is small, heterogeneous, and lacks robust replication, making efficacy in humans not yet proven.

Lion's Mane contains immunomodulatory polysaccharides and bioactive compounds that enhance immune cell activity in laboratory and animal studies, but human clinical efficacy for immune function has not been established—only one human observational study exists.

Alpha-GPC shows plausible immune-modulatory effects in animal models and limited human observational data, but there is no human RCT evidence demonstrating proven efficacy for immune support. Current evidence is too preliminary to draw definitive conclusions about clinical benefit.

Bacopa monnieri shows immunomodulatory potential through in-vitro and mechanistic studies, but human efficacy for immune function remains unproven. Only 2 human RCTs exist, and both focus on cognitive outcomes rather than primary immune endpoints.

Phosphatidylserine is a key immunological signal involved in apoptotic cell recognition and phagocytosis, but evidence of clinical efficacy for immune support in humans is essentially absent. All mechanistic understanding comes from animal models, in vitro studies, and one small human observational study in multiple sclerosis.

CDP-Choline shows plausible immunomodulatory effects in human studies, primarily through reduced inflammatory markers (histamine, IL-1) in Alzheimer's disease patients. However, evidence for direct immune benefits remains limited to small observational studies with no large randomized controlled trials demonstrating clinically meaningful immune outcomes.

Panax ginseng shows plausible immunomodulatory effects through multiple mechanistic pathways in animal and in-vitro studies, but human efficacy for immune support remains largely unproven. Only one human RCT was identified among 50 total articles, and it focused on athletes rather than general immune function.

Huperzine A shows immunomodulatory effects in animal models of sepsis, autoimmune encephalomyelitis, and colitis, primarily through activation of the cholinergic anti-inflammatory pathway. No human RCTs exist for immune function; evidence is limited to animal studies and mechanistic reviews.

PQQ shows consistent immune-supporting effects in animal and cell studies, with evidence of anti-inflammatory, antioxidant, and immune cell modulation. However, human efficacy for immune function remains unproven—only 2 human RCTs exist, neither of which directly measured traditional immune markers.

Noopept shows consistent immunomodulatory effects in animal studies, including enhanced macrophage activity, increased antibody production to amyloid-beta, and anti-inflammatory properties. However, no human RCTs exist for immune function, limiting the ability to establish proven efficacy in humans.

Phenylpiracetam shows immunomodulatory effects in animal models, with evidence suggesting it can normalize cytokine levels and improve immune function under both immunosuppressed and hyperimmune conditions. However, no human clinical trials exist to confirm efficacy in humans.

Vinpocetine demonstrates anti-inflammatory effects on immune cells in cell culture and animal models through NF-κB inhibition, but human evidence is limited to 2 small observational studies without control groups. Efficacy in humans for immune support remains unproven.

Bromantane shows immunostimulant effects in animal studies and limited mechanistic evidence, but there are no human clinical trials demonstrating efficacy for immune function. Evidence remains preliminary and plausibility-based rather than proven.

L-glutamine shows plausible immunological benefits through mechanistic studies and limited human data, but efficacy for immune function in humans remains unproven. A 2024 meta-analysis found no significant effect on gut permeability, and the strongest human evidence comes from a single small observational COVID-19 study.

Acetyl-L-carnitine shows immunomodulatory effects in preliminary human studies and animal models, primarily enhancing antibacterial immune responses and reducing inflammatory markers in specific disease contexts. However, efficacy is not conclusively proven—evidence consists of small human trials, mixed results across conditions, and lacks independent replication in large-scale RCTs.

Glycine shows immunomodulatory potential in animal models and mechanistic studies, but human evidence for immune benefits is extremely limited. Only one small open-label human study exists (n=8 HIV patients), showing indirect immune benefits through glutathione restoration rather than direct immune enhancement.

5-HTP shows plausible immunomodulatory effects in animal and limited human studies, with evidence suggesting it may enhance certain immune markers and reduce allergic inflammation. However, human efficacy data are minimal and inconsistent; most robust evidence comes from animal models, preventing confident conclusions about clinical immune benefits.

GABA shows immunomodulatory potential in animal and limited human studies, with evidence suggesting it can enhance certain immune markers under stress, but proven efficacy in humans remains limited to small pilot studies with unclear clinical significance.

Beta-alanine shows plausible immune-modulating effects primarily through its metabolite carnosine, with one small human RCT demonstrating reduced inflammatory markers (CRP and IL-6) in athletes. However, efficacy in humans is not yet proven, and evidence relies heavily on mechanistic animal and in-vitro studies rather than robust clinical trials.

L-citrulline shows plausible immune-supporting mechanisms in animal and limited human studies, primarily through nitric oxide production and arginine recycling, but human efficacy for immune function remains unproven with only 1 small RCT and 4 observational studies available.

Taurine shows immune-modulating potential in animal and limited human studies, with evidence suggesting benefits for inflammatory markers and immune cell function. However, only one small double-blind RCT in humans exists, and efficacy for immune function specifically remains unproven.

Leucine supplementation modulates immune markers and inflammatory pathways in animal models and limited human studies, but evidence of clinically meaningful immune benefits in humans remains preliminary. Most efficacy data come from animal studies or mechanistic assessments rather than robust human immune outcome trials.

Tryptophan supplementation shows plausible immune-modulatory effects through activation of tryptophan metabolic pathways (kynurenine, serotonin, indoles), but efficacy for immune health is not proven in humans. Limited human RCT evidence exists, with most support coming from mechanistic observational studies and animal models.

L-lysine supplementation shows plausible immune-modulating effects in animal models of autoimmune hepatitis and stress-induced gut dysbiosis, but no human trials have been conducted. Efficacy in humans remains unproven.

Retatrutide shows promise for immune-related cancer protection in preclinical models through immune reprogramming, but evidence is limited to animal studies with no human trials demonstrating efficacy for immune function as a primary outcome.

Cortistatin shows immunomodulatory and anti-inflammatory properties in animal models and in vitro studies, but lacks human RCT evidence. No clinical trials have demonstrated efficacy for immune health in humans.

Dulaglutide shows immunomodulatory effects in animal models of autoimmune disease and NASH, but evidence for immune benefit in humans is limited to safety data and one case report of immune-mediated kidney injury. No human trials demonstrate positive immune outcomes.

Exenatide shows anti-inflammatory effects in immune cells and animal models of autoimmune disease, but direct evidence of immune-enhancing efficacy in humans is limited to small, non-randomized studies in specific contexts (islet transplantation, type 1 diabetes). Most robust human data concerns safety rather than immune improvement.

Ghrelin shows anti-inflammatory and immunomodulatory properties in preclinical and animal models, with emerging evidence from a few small human observational studies suggesting potential immune benefits. However, no robust human RCTs demonstrating efficacy for immune function exist, and most mechanistic evidence comes from animal studies or reviews.

Lanreotide shows immunomodulatory effects in neuroendocrine tumor patients, promoting Th1 cytotoxic immune responses and altering T cell signaling. However, evidence of clinical immune benefit remains preliminary and is primarily derived from small observational studies and mechanistic investigations rather than controlled trials.

Lixisenatide shows anti-inflammatory and antioxidant effects in animal models and cell culture, but no human clinical trials for immune function exist. Efficacy in humans remains unproven.

Nesfatin-1 is associated with immune dysregulation in several inflammatory and autoimmune diseases, but evidence of therapeutic efficacy is limited to animal models and observational human studies. No RCTs demonstrate that nesfatin-1 supplementation improves immune function.

Neuropeptide Y shows immunomodulatory properties in animal and limited human studies, with evidence suggesting it can attenuate excessive immune responses and reduce inflammation in specific disease contexts. However, no human randomized controlled trials demonstrate efficacy, and evidence remains primarily mechanistic rather than clinically proven.

Orexin-A shows immunomodulatory potential in animal models and limited human observational studies, particularly for inflammatory bowel disease and neuroinflammation, but lacks human RCT evidence demonstrating clinically meaningful immune improvements.

P21 shows immunomodulatory effects in animal models, particularly against influenza virus infection and inflammatory arthritis, but human evidence is limited to small observational studies and mechanistic research. Efficacy in humans for immune support remains unproven.

PACAP shows immunomodulatory and anti-inflammatory effects in multiple animal and in-vitro models, but clinical efficacy in humans for immune support remains unproven. Only 2 human observational studies exist, neither demonstrating direct immune-boosting benefits.

Pemvidutide has not been directly studied for immune function in the abstracts provided. Evidence is limited to mechanistic reviews suggesting GLP-1/GIP dual agonists may have immunomodulatory potential, but no human trials or direct efficacy data for immune health exist for this compound.

Peptide YY shows associations with immune markers in post-acute pancreatitis patients and appears in various mechanistic pathways related to gut-brain-immune communication, but no human trials demonstrate that PYY supplementation actually improves immune function in healthy people or patients with immune-related diseases.

Setmelanotide shows promise for immune-related conditions through melanocortin receptor agonism, but evidence is limited to one human case report of urticaria resolution and theoretical mechanistic discussion. Efficacy is plausible but not proven in humans.

Survodutide has not been directly studied for immune function in humans. Evidence is limited to mechanistic reviews and observational studies of related GLP-1/GIP dual agonists (tirzepatide, semaglutide) showing immunomodulatory properties, but no direct efficacy data for immune outcomes exists.

Teriparatide shows immunomodulatory effects in limited human studies and multiple animal models, but there is no direct evidence that it improves immune function as a clinical outcome. The evidence suggests teriparatide interacts with immune pathways rather than demonstrably enhancing immunity.

Thymulin is a zinc-dependent thymic hormone with established effects on T-cell development and immune function demonstrated in multiple human observational studies and animal models, but only one small human RCT exists and no large-scale RCTs confirm clinical efficacy for immune support in healthy populations.

NAD+ shows plausible immune-supporting mechanisms in animal and mechanistic studies, but there are no human RCTs demonstrating actual efficacy for immune function. Evidence is primarily from rodent models and reviews of metabolic pathways.

CaAKG (calcium alpha-ketoglutarate) shows plausible immune-supportive effects based on mechanistic research and animal studies, but robust human clinical trial evidence for immune function improvement is absent. One human RCT exists, but it studied glutathione/resveratrol precursors, not CaAKG directly.

Calcium supplementation shows plausible immune-modulatory effects in limited human studies, but efficacy for preventing infections or improving immune function remains unproven. Most evidence is mechanistic or shows mixed/null results.

Manganese supplementation shows consistent effects on immune markers and antioxidant defense in animal models (poultry and livestock), but no human trials exist to prove efficacy in humans. Evidence is limited to animal studies and reviews.

Vitamin B1 shows plausible immune-enhancing mechanisms in animal and cell culture studies, but human evidence for immune benefits is limited to observational data on deficiency correction and one small mechanistic study. No rigorous human RCTs demonstrate that B1 supplementation improves immune function in adequately nourished individuals.

Vitamin B2 shows immunomodulatory potential in animal and limited human studies, but evidence of efficacy in actual immune function improvements is preliminary. Most data comes from mechanistic studies or animal models; human evidence is minimal.

Folate supplementation shows inconsistent and conflicting effects on immune function. While mechanistic studies suggest folate influences immune-related gene pathways, human evidence is limited, and some studies report potentially harmful immune outcomes (e.g., increased respiratory infections in children, impaired CD8+ T cell function in cancer models).

Luteolin shows consistent mechanistic effects on immune pathways in animal and cell studies, but human evidence for immune function is limited to observational reports and theoretical analyses. No human RCTs demonstrate that luteolin supplementation improves immune outcomes in healthy or diseased populations.

Ginger shows immunomodulatory effects in animal models of autoimmune and inflammatory diseases, but evidence from human studies is limited to one small observational study and one mixed-ingredient clinical trial where ginger's individual contribution cannot be isolated.

Lecithin shows some promise for immune function in animal studies, with one rat study demonstrating increased macrophage phagocytosis and lymphocyte response. However, evidence is limited to a single human observational study and two aquaculture/fish reviews, making human efficacy unproven.

Cinnamon shows immunomodulatory properties in animal and in vitro studies, with some evidence for anti-inflammatory effects. However, human evidence for immune-specific benefits is extremely limited, and most clinical trials focus on metabolic outcomes rather than immune function.

Vitamin K1 shows immunomodulatory potential in preliminary studies, but human evidence for immune benefits is sparse and inconsistent. Most supportive data comes from animal models, older mechanistic studies, and observational work, with only one small RCT directly testing immune outcomes in a disease state.

Lycopene shows plausible immune-modulating effects in animal and small human studies, but efficacy in humans remains unproven. Evidence is primarily from animal models (poultry, rodents) with only 3 small human RCTs showing mixed immunological changes.

MCT oil shows plausible immune-supporting effects in critically ill and surgical patients, with some evidence of improved lymphocyte counts and immune cell function. However, efficacy is not consistently proven—most positive findings come from small human studies or animal models, and several larger trials show no significant immune benefit.

A single small human RCT shows that nitrate-rich beetroot juice produces some markers consistent with reduced inflammation (decreased monocyte-platelet aggregates and CD11b-expressing granulocytes) in older adults, but evidence of actual immune improvement is limited and unconfirmed.

Sea moss extract shows immunomodulatory activity in animal and in-vitro studies, with polysaccharide components enhancing immune gene expression and reducing pathogenic bacteria virulence. However, no human clinical trials exist to demonstrate efficacy in people.

Yellow dock shows antimicrobial and anti-inflammatory activity in laboratory and animal studies, but there is no human clinical evidence demonstrating efficacy for immune function. One human RCT found no significant benefit for cancer-related quality of life.

Manuka honey demonstrates potent antimicrobial and antibiofilm activity against pathogenic bacteria in laboratory and animal studies, but human evidence is limited to one small phase 1 trial with modest clinical outcomes. Efficacy for immune function specifically is not directly proven.

Slippery elm shows plausible immune-supporting effects in one human RCT and one animal study, but efficacy in humans is not yet proven. The human study found microbiota changes theoretically linked to immunity, not direct immune improvements.

DHEA shows immunomodulatory effects in laboratory and animal studies, with some evidence of immune cell activation in elderly populations, but robust human RCT evidence demonstrating clinically meaningful immune benefits is absent. Most claims remain theoretical or based on mechanistic studies rather than proof of efficacy.

Evidence for BPC-157's immune effects comes primarily from theoretical speculation and limited honeybee studies. No proven efficacy in human immune function exists.

GHK-Cu shows anti-inflammatory and antioxidant properties in rodent models and cell culture, but there is no human evidence demonstrating efficacy for immune support. All evidence is preclinical (1 animal study, 3 in-vitro studies).

Semax's immunomodulatory effects on proinflammatory markers have only been demonstrated in a rat brain ischemia model; no human efficacy data exists for immune support, making claims of immune benefit purely preliminary.

AOD-9604 has no demonstrated efficacy for immune health. The single available study examines cartilage regeneration in an osteoarthritis rabbit model, which is unrelated to immune function.

No human evidence demonstrates that Melanotan 1 improves immune function. Available abstracts address immunogenicity (antibody formation against the peptide) and computational predictions of antibiotic activity, not actual immune enhancement.

Cartalax has not been studied for immune function. The single available study examined neuronal differentiation in stem cells, which is unrelated to immune health.

No direct evidence supports ibutamoren's efficacy for immune function. The single available abstract is a review of growth hormone and IGF-I in Alzheimer's disease with no mention of ibutamoren or immune outcomes.

Only a single review article exists examining IGF-1R signaling mechanisms in cell culture; no human trials, animal studies, or efficacy data for immune function are reported.

This abstract describes the development and validation of a monoclonal antibody against oxytocin for research purposes, not the immunological effects of oxytocin itself. No efficacy data for immune function is reported.

Nattokinase has not been studied for immune function in humans. The available evidence consists of mechanistic reviews, animal models, and in-vitro studies suggesting potential immunomodulatory pathways, but no human trials demonstrate efficacy for immune health.

Apigenin has not been studied in humans for immune support; only a single animal study in broiler chickens with necrotic enteritis exists, showing improved immune markers and intestinal health in this specific disease model.

Fadogia agrestis showed in vitro antiplasmodial activity against Plasmodium falciparum in a single ethnobotanical survey, but there is no human evidence, animal studies, or clinical efficacy data supporting immune system benefits.

Valerian root has not been proven effective for immune function. The six available studies focus primarily on sleep quality and antimicrobial activity in vitro, with no direct evidence of immune system enhancement in humans.

No direct evidence demonstrates that passionflower improves immune function. The single available abstract is a review of ethnopharmacological practices that mentions passionflower tangentially but provides no clinical data on efficacy for immune health.

Lithium orotate has not been directly studied for immune function in humans or animals. The available abstracts examine lithium chloride's effects on seizures, cognition, and neuroprotection—none of which are immune-related endpoints.

Hyaluronic acid has been extensively studied for osteoarthritis and joint health, but the abstracts provided contain NO studies specifically investigating hyaluronic acid for immune function. All included studies examine musculoskeletal, dermatological, or vaccine delivery applications, making this compound-goal pair unsuitable for immune health evaluation based on the provided evidence.

Piracetam has no demonstrated efficacy for immune function in humans. The 50 articles retrieved are primarily about levetiracetam (a related but distinct compound) for epilepsy, not piracetam for immunity.

No evidence supports aniracetam for immune function. The retrieved abstracts discuss aniracetam's effects on glutamate signaling and cognition in animal models, but none directly evaluate immune outcomes or immune-related endpoints.

The 50 abstracts provided do not demonstrate that uridine supplementation improves immune function in humans. Most studies focus on uridine's role in viral infections (HCV, WELV, coronaviruses, flaviviruses) as part of antiviral drug mechanisms, not as an immune-supporting supplement.

Centrophenoxine has not been studied for immune function in humans. One in-vitro study showed modest enhancement of neutrophil phagocytosis (8.8% increase), but this finding is isolated and lacks human validation or clinical relevance.

NSI-189 was identified as a differential serum metabolite in thyroid autoimmunity patients during early pregnancy, but this observational finding provides no evidence that NSI-189 has any immune-modulating efficacy or clinical benefit.

No evidence demonstrates sulbutiamine's efficacy for immune function. The three available abstracts do not study sulbutiamine's effects on immune outcomes; instead, they examine it in cancer metabolism and parasite models unrelated to immune support.

A single rat study shows pramiracetam increases nitric oxide synthase activity in the brain cortex, but there is no evidence of immune system effects or clinical relevance to immune function in any study.

D-aspartic acid has not been studied for immune function in humans. The abstracts discuss D-aspartic acid's role in bacterial biofilm disruption and neural signaling, but provide no evidence of immune-enhancing effects in any organism.

L-Carnosine has theoretical immunoregulatory properties based on mechanistic review, but no human clinical trials or animal studies specifically demonstrating immune efficacy are presented in the available literature.

L-serine is not directly studied for immune function in the provided abstracts. The only relevant mentions are incidental—as an amino acid component in clove (Study 11) and in a D-serine conversion pathway (Study 16)—with no human trials demonstrating efficacy for immune goals.

Tirzepatide does not improve immune function for the stated goal. Evidence consists primarily of case reports and observational studies documenting immune-related adverse events (thrombocytopenia, vasculitis) and incidental improvements in unrelated inflammatory conditions (urticaria, folliculitis). No RCTs or human studies demonstrate direct immunological benefit.

Abaloparatide has no demonstrated efficacy for immune function. All evidence relates to bone metabolism and osteoporosis treatment; immune outcomes are neither studied nor reported.

Cagrilintide is mentioned only as an amylin analog in a review of peptide aggregation and immunogenicity risks; there is no evidence that it improves immune function. The only human-relevant study discusses nutritional challenges during weight loss, not immune outcomes.

IGF-1 DES has been studied only in vitro to characterize IGF-1 receptor binding on immune cells; no efficacy data demonstrates that it actually improves immune function in any living organism.

Linaclotide is mentioned as a treatment option for IBS-related symptoms in multiple review articles, but the abstracts provide no evidence that it improves immune function. The compound's mechanism relates to gastrointestinal secretion and motility, not immune outcomes.

Matrixyl has not been studied for immune function in humans. The only available evidence comes from in-vitro studies showing that modified versions of Matrixyl's parent peptide (pentapeptide-4) have antimicrobial activity against bacteria in laboratory conditions, but this does not demonstrate that Matrixyl itself improves immune function in living organisms.

Octreotide has not been demonstrated to improve immune function. The available evidence shows either neutral effects, impaired immune responses, or use in diagnostic imaging of immune-related conditions, but no proven immunoenhancing efficacy.

Pramlintide has no demonstrated efficacy for immune function. The abstracts discuss pramlintide's effects on glucose metabolism, gastric emptying, and weight management in diabetes, but contain no evidence of immune-enhancing or immune-modulating benefits.

C-10 (decanoic acid lipopeptide modifications) shows antimicrobial activity in laboratory and animal studies, but no human efficacy data exists for immune support. Evidence is limited to in-vitro peptide synthesis studies and one animal model.

Vitamin B5 (pantothenic acid) reversed endometrial injury in a mouse vagotomy model, but no human evidence exists for immune benefits. Animal findings are promising but do not prove efficacy in humans.

Zeaxanthin has not been proven effective for improving immune function in humans. The available evidence focuses on retinal and ocular health, with only theoretical immune-related mechanisms described in review articles.

Apple cider vinegar has not been studied for immune function in humans. Only two animal studies (broiler chickens and shrimp) show modest improvements in specific immune markers, but these findings cannot be meaningfully extrapolated to human immune health.

No evidence demonstrates that kelp improves immune function in humans. The only animal study found no significant differences in immune markers (antibody production, virus replication, immune response) between kelp-supplemented and control groups.

There is no evidence that chlorophyll improves immune function in humans. The single available study examines chlorophyllin's antifungal properties against a plant pathogen in postharvest citrus treatment, which is unrelated to human immune health.

No evidence demonstrates that molybdenum improves immune function in humans or animals. The single available abstract is a biochemistry review of fruit fly enzyme structure with no relevance to immune health.

Caffeine has not been demonstrated to improve immune function in humans. The available evidence consists of mechanistic studies in fish and a single animal model showing immune-related benefits, but no human clinical trials have directly assessed immune outcomes.